Triptorelin, a decapeptide and synthetic analogue of gonadotropin-releasing hormone (GnRH), plays a crucial role in regulating sex hormone release. Widely used in medicine, it has shown therapeutic efficacy in hormone-responsive cancers like prostate and breast cancer, endometriosis, and precocious puberty.
Triptorelin acts by binding to GnRH receptors on the anterior pituitary gland. Initially, it stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. However, according to research, prolonged administration leads to receptor desensitization and downregulation, causing reduced secretion of LH and FSH. This results in a chemical castration state, which aids in managing hormone-dependent conditions.
Showing all 3 results
[1] https://pubmed.ncbi.nlm.nih. gov/15082521/
[2] https://pubmed.ncbi.nlm.nih. gov/21788033/
[3] https://pubmed.ncbi.nlm.nih. gov/11978277/
[4] https://pubmed.ncbi.nlm.nih. gov/19332438/
[5] https://pubmed.ncbi.nlm.nih. gov/11208825/
[6] https://pubmed.ncbi.nlm.nih. gov/22733160/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://france.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States